Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *9/13/2018: Initial FDA approval | + | *9/13/2018: Initial FDA approval for adult patients with relapsed or refractory [[Hairy cell leukemia|hairy cell leukemia (HCL)]] who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). ''(Based on Study 1053)'' |
==Also known as== | ==Also known as== | ||
Revision as of 20:43, 10 May 2021
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 9/13/2018: Initial FDA approval for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). (Based on Study 1053)
Also known as
- Generic name: moxetumomab pasudotox-tdfk
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti